T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC
Clinical trial NCT03784599 · TERMINATED
Trial details
- NCT number
- NCT03784599
- Sponsor
- The Netherlands Cancer Institute
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-12-18
- Primary completion
- 2021-05-17
- Enrollment
- 28
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.